Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors.
A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA(2) (EC(50) = 3.7 +/- 0.2 microM and 700 +/- 22 nM, respectively), yet selective antagonists of LPA(3) (K(i) = 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA(1). Neither LPA(1) nor LPA(3) receptors were activated by FAPs; in contrast, LPA(2) was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA(2) by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC(50). The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA(3)-expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P(1,2,3,5) receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA(2).
Virag
Tamas
T
Department of Physiology, University of Tennessee Health Science Center, Memphis 38163, USA.
Elrod
Don B
DB
Liliom
Karoly
K
Sardar
Vineet M
VM
Parrill
Abby L
AL
Yokoyama
Kazuaki
K
Durgam
Gangadhar
G
Deng
Wenlin
W
Miller
Duane D
DD
Tigyi
Gabor
G
D000818:Animals; D002460:Cell Line; D006801:Humans; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D010755:Organophosphates / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000819:agonists* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D049368:Receptors, Lysophosphatidic Acid; D014982:Xenopus laevis
D010755:Organophosphates; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D049368:Receptors, Lysophosphatidic Acid